Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Amplifications and, less frequently, translocations are the most common findings for PDL1/PDL2 and JAK2 in lymphomas.
|
30132131 |
2019 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Although PD1/PDL1 has been extensively studied in variety of lymphomas, there are few reports characterizing their expression in EBV-positive LPD.
|
29084057 |
2019 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PD-L1 is a targetable immune check-point molecule that is expressed on neoplastic cells in various cancers, including a subset of lymphomas.
|
30938862 |
2019 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we report that myeloid-deficient Becn1 (Becn1ΔM) mice developed neutrophilia, were hypersusceptible to LPS-induced septic shock, and had a high risk of developing spontaneous precursor B cell (pre-B cell) lymphoma with elevated expression of immunosuppressive molecules programmed death ligand 1 (PD-L1) and IL-10.
|
31503548 |
2019 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
As a oncogenic biomarker of B-cell lymphoma, serum miR155 was related to lymphoma progression through modulating PD-1/PD-L1-mediated interaction with CD8+T cells of tumor microenvironment, indicating the sensitivity of B-cell lymphoma to PD-L1 blockade.
|
30925928 |
2019 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas.
|
31185600 |
2019 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we review the clinicopathological significance of PD-1/PD-L1 expression in lymphomas.
|
31704289 |
2019 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These results highlight the interest of therapies targeting the PD-1/PD-L1 axis in activated lymphomas with PD-L1 expression, with possible synergies with tyrosine kinase inhibitors.
|
31382969 |
2019 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibiting the immune checkpoint through naturalizing programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) is proved to be a successful therapeutic regime for lymphoma.
|
31570691 |
2019 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PD-L1 is highly expressed in B-cell malignant lymphomas and negatively correlated with treatment time.
|
30867773 |
2019 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we describe results using PD-L1 immunohistochemistry during routine diagnostics in lymphoma.
|
29380399 |
2018 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal center B cell-like (non-GCB) subtype.
|
30458835 |
2018 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, this study aimed to determine the clinicopathological relevance of HLA and β2M expressions in ATLL cells and PD-L1 expression in lymphoma or stromal cells and predict the overall survival of patients with ATLL.
|
29297942 |
2018 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we outline the rationale for investigation of PD-1-PD-L1 immune-checkpoint blockade in lymphomas and discuss their prospect of applications in clinical treatment.
|
29128997 |
2018 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
|
29695766 |
2018 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, we show that a clinically relevant anti-human CD27 mAb, varlilumab, similarly synergizes with PD-L1 blockade for protection against lymphoma in human-CD27 transgenic mice.<b>Conclusions:</b> Our findings suggest that suboptimal T-cell invigoration in cancer patients undergoing treatment with PD-1 checkpoint blockers will be improved by dual PD-1 blockade and CD27 agonism and provide mechanistic insight into how these approaches cooperate for CD8<sup>+</sup> T-cell activation.<i></i>.
|
29514845 |
2018 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas.
|
29122656 |
2018 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we demonstrate actual knowledge on immune checkpoint function and its impact on development of new modality of antineoplastic treatment, using, for example, anti-CTLA-4 or PD-1/PD1 ligand (PD-L1) monoclonal antibodies in malignant lymphomas.
|
29850620 |
2018 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Overall, our study reveals a previously unrecognized mechanism by which chemotherapy induces tumor immune evasion by upregulation of PD-L1 in bone marrow stromal cells, and provides new evidence for the combination of chemotherapy and anti-PD-L1/PD-1 as an effective strategy for treatment of lymphoma and other cancers.
|
28218497 |
2017 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the results in other lymphoid malignancies have not been so striking, blockade of the PD-1/PD-L1 axis has led to meaningful responses in other lymphoma types such as diffuse large B-cell lymphoma, follicular lymphoma or several T-cell lymphomas.
|
28685821 |
2017 |
Lymphoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Finally, we conclude that down-regulated expression of miR-143 and up-regulation of its direct target B7H1 may indicate a novel therapeutic method for radiation-induced thymic lymphoma by increased expression of miR-143 or inhibition of B7H1.
|
28736328 |
2017 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggest that sPD-L1 could be a prognostic predictor for NNKTL and open up the possibility of immunotherapy of this lymphoma using PD-1/PD-L1 axis inhibitors.
|
28349165 |
2017 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The clinical efficacy of therapeutic modulation of the PD1-PDL1 pathway has been recently shown in classical Hodgkin lymphoma (cHL), but little is known about the frequency and diagnostic and prognostic importance of PDL1 expression in lymphomas.
|
27045512 |
2016 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We investigated PD-L1 status in a variety of treatment resistant lymphomas.
|
27861596 |
2016 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the significance of PD-L1/2 expressions on macrophages in lymphoma progression has never been clarified, an IL-27-Stat3 axis might be a target for immunotherapy for lymphoma patients.
|
27564404 |
2016 |